Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Bio-Gate AG is a company specializing in the field of innovative health technology. Its primary focus is on developing and marketing products that incorporate antimicrobial solutions, particularly for medical and cosmetic applications. The company is renowned for its pioneering use of micro-silver technology, which is utilized to enhance the safety and efficacy of medical devices, consumer healthcare products, and coatings. Bio-Gate's solutions are instrumental in reducing microbial colonization and infection rates, making them highly valuable in healthcare settings such as hospitals and clinics. The firm's offerings also extend to the pet care industry, where antimicrobial coatings are used on pet products to enhance hygiene and safety. Through collaborations with various multinational companies, Bio-Gate AG's technology influences a wide range of sectors, solidifying its role as a key player in the global market for antimicrobial solutions. The company's headquarters is in Nuremberg, Germany, from where it serves its clients worldwide with cutting-edge innovations designed to promote health and safety across industries.
The business is unprofitable at the operating level (-15.25% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 4.9%, steady but not accelerating.
ROIC dropped from -48.35% to -51.86%, capital efficiency is deteriorating. Negative free cash flow of -€1M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€7M
▲ +4.9% YoY
Net Income (TTM)
-€1M
▲ +26.8% YoY
Op. Margin
-15.25%
▲ +7.5pp YoY
ROIC
-51.86%
▼ -3.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€1M
▼ -6.9% YoY
Op. Cash Flow (TTM)
-€1M
▲ +4.6% YoY
Net Debt
-€652K
Net Cash Position
Cash & Equiv.
€705K
3Y CAGR: +7.3%
Continue Research